Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. The company develops treatments for lipodystrophy . licensed the product from TaiMed Biologics, Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 75. L. It's a different kind of fat that may require a different type of treatment. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, is pleased to announce that new data featuring its investigational sortilin 1 (SORT1)-targeting peptide-drug conjugate technology will be presented in three posters at the American. com uses cookies on this site. MONTREAL, Sept. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Stockhouse. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. The price has fallen in 5 of the last 10 days. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. , that crews have been mobilized to prepare for the 2022 exploration program at the Treaty Creek property, located in the heart of the. 521. 25. . The money will be used to grow the company’s FDA-approved drugs, Egrifta SV (tesamorelin), used for the reduction of excess. $109. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Revenues have been growing at an average rate of 10. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. ( THTX 3. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. . (TH. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The company reported ($0. Senior Director, Investor Relations. By continuing to use our service, you agree to our use of cookies. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stockhouse. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 11, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. This news release constitutes a "designated news release" for the purposes of. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. By continuing to use our service, you agree to our use of cookies. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. " The 12-month stock price forecast is $18. (THTX) stock. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. According to 3 analysts, the average rating for THTX stock is "Buy. 18% on the last trading day (Wednesday, 25th Oct 2023), rising from $1. Theratechnologies Inc. There are 102 news items for this page. 40% on the last trading day (Friday, 17th Nov 2023), rising from $1. One reason for that is that this tier does not include penny stocks. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. In 2022, THTX's revenue was 80. Stockhouse. 16%. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. 86%. FDA for its IV push form of administration of Trogarzo. (TSX-V: TLT, Forum) has demonstrated proof-of-concept for its Canadian-made COVID-19 vaccine. Stockhouse. com. Montréal, Québec, Canada . Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. MONTREAL, April 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Following the release, Knight will hold a conference call and audio webcast. com uses cookies on this site. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. (2019-08-07 | TSX:TH) Jean-Denis Talon Retires From Theratechnologies' Board of Directors. B2Gold Declares Fourth Quarter 2023 Dividend. com uses cookies on this site. $44. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Patient assistance: 833-238-4372. 3 brokerages have issued 1-year price objectives for Theratechnologies' shares. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. We also use them to share usage. 1-514-336-7800. . (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. Cookies are used to offer you a better browsing experience and to analyze our traffic. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. com. The business had revenue of $27. Phone Number 15143319691. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. T. We currently market prescription products for people with. Cookies are used to offer you a better browsing experience and to analyze our traffic. First Quarter Fiscal 2022 Financial Results. Share your ideas and get valuable. 2015 Peel St 11TH Fl, Montreal, Quebec, H3A 1T8, Canada. By continuing to use our service, you agree to our use of cookies. Stockhouse. Theratechnologies Provides Details About R&D Day Webcast. We also use them to share usage. [at noodls] - Montreal, Canada - April 17, 2015 - Theratechnologies Inc. T. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. It is the Company’s proprietary peptide linked to. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. 24, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. TH | March 7, 2023. The abstract and poster can be found on Theratechnologies’ website. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Gary Littlejohn. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Learn why it. Stockhouse. 5% workforce reduction. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX) ), a biopharmaceutical company focused on the development. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. 23 to a day high of $1. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Inc. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . com. We also use them to share usage. US Headquarters. Thank you. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. Lead drug EGRIFTA (tesamorelin for injection) is being marketed for the reduction of excess abdominal fat in HIV-infected patients with. MONTREAL, July 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Gain a better understanding of ETFs with our ETF Insights and ETF 101 resource. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 [email protected]%) S&P 500. Data presented at AMCP Nexus 2023. Theratechnologies Inc. Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. MONTREAL, Aug. We also use them to share usage. Theratechnologies (TH) provided business highlights and financial results for the second quarter and first half of fiscal year 2022; For the three- and six-month periods ending May 31, 2022, consolidated revenue was US$19,268,000 and US$37,825,000, compared to US$17,787,000 and US$33,217,000 for the same periods last year,. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. $30. 9% more than in 2021. m. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. Cookies are used to offer you a better browsing experience and to. . (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. [email protected] Inc: Overview. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced an update on the plan to amend and optimize the protocol of its Phase 1 oncology. MONTREAL, April 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. We currently market prescription products for people with HIV in the United States. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 08). 40%) (As of 11/17/2023 ET) Compare Today's Range $1. 20% from a day low at $1. com. Stockhouse. com uses cookies on this site. Trogarzo ® is a long-acting, CD4-directed, post-attachment HIV-1 inhibitor. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies (TSX: TH) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including. TH | Complete Theratechnologies Inc. The FDA granted fast track designation to TH1902 as a single agent for. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. (CSE: KOG) (" KO Gold " or the " Company ") is pleased to announce that the common shares of the Company will commence trading on the Canadian Securities Exchange (CSE) effective at the open of business on Wednesday, October 11, 2023, under the symbol " KOG ". Biopharmaceutical company Theratechnologies Inc. Apr 14, 2020, 8:30 a. Cookies are used to offer you a better browsing experience and to analyze our traffic. We currently market. MONTREAL, Jan. (TH. The abstracts are now available at aacr. 36 morning pop. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. 9 million and US$19. com uses cookies on this site. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). By continuing to use our service, you agree to our use of cookies. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Paul Levesque - President. Theratechnologies, Inc. 06 million, an increase of 14. 71%. (THTX) stock quote, history, news and other vital information to help you with your stock trading and investing. 6. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ Technology TM for cancer drug development targeting SORT1. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. 1M. (2018-12-03 | TSX:TH) Theratechnologies Appoints New Chief Commercial Officer. Cookies are used to offer you a better browsing experience and to analyze our traffic. However, only about 4% of the stocks on the OTC market fall into this category. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported the voting results from its annual meeting of shareholders held today in a virtual-only setting. Track Theratechnologies Inc. MONTREAL, Nov. 9 million, adjusted EBITDA of $2. Stockhouse. Story. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. 18, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 4%. Further information about Theratechnologies is available on the Company's website at , on SEDAR at and on. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. We also use them to share usage. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. : Nasdaq Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Q4 2022 consolidated revenue growth of 14. com 10/16/2023. Stockhouse. org. TH | July 20, 2023. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. 10% least volatile stocks in CA Market. Montreal-based biopharmaceutical company Theratechnologies Inc. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. A live webcast of Dr. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. US Headquarters. Contact Email communications@theratech. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, Dec. 40%. By continuing to use our service, you agree to our use of cookies. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. 2022 Revenue Guidance Theratechnologies anticipates fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. (TSX: EXRO) (OTCQB: EXROF) (the "Company" or "Exro" ), a leading clean technology company which has developed a new class of power electronics for electric motors and powertrains, announced today its financial results for the three months ended March 31, 2022. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30,. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. T. We also use them to share usage. Cookies are used to offer you a better browsing experience and to analyze our traffic. The webinar will also address system-level barriers and present real-world. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | September 5, 2023. FY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance; FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash. We also use them to share usage information with our partners. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. com uses cookies on this site. Theratechnologies is pepped up on peptides. VANCOUVER, British Columbia, Nov. com. Senior Director, Communications & Corporate Affairs. TORONTO, Sept. A high-level overview of Theratechnologies Inc. -986. com uses cookies on this site. com uses cookies on this site. 2% per year. Cookies are used to offer you a better browsing experience and to analyze our traffic. Theratechnologies Unveils New Positive Data for Its Investigational Peptide-Drug Conjugates Targeting Sortilin Positive Cancers Stockhouse. Track Theratechnologies Inc. Biopharmaceutical company Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. View real-time stock prices and stock quotes for a full financial overview. 3. Q3 2023 consolidated revenue of $20. 65 per cent to C$1. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. sBLA for F8 formulation of tesamorelin submitted to FDA. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. 9 million and US. . T. For investor inquiries: Leah Gibson. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. Theratechnologies Inc. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 8 million. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies had a negative net margin of 36. D. Consensus forecasts updated Jul 21. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 49) by $0. The firm offers its product under the brand name of. 89 52. These companies provide a lot of detail to the OTC Markets Group including audited financials. 28 $1. Phone Number (514) 336-7800. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. However, it did not meet the equivalence limits of 0. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 72%. 17. Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022. Stockhouse. Their THTX share price targets range from $36. Once expert advice is considered, the Company. We also use them to share usage information with our partners. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. About Theratechnologies. - 2023 Q3 positive adjusted EBITDA to be. MONTREAL, Sept. Cookies are used to offer you a better browsing experience and to analyze our traffic. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Cookies are used to offer you a better browsing experience and to analyze our traffic. We changed the address of the Stockhouse website from to stockhouse. See a list of the most recent Stock Forum posts on Stockhouse. US Headquarters. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. - Issued and outstanding common shares to be consolidated on the basis of 1 post. (2015-07-23 | TSX:TH) Theratechnologies Announces $9,600,000 Firm Offering of Units and Filing of Preliminary Short Form Prospectus. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. GlobeNewswire. Unveiling Silvercorp's golden potential at the Ying Mining District. com uses cookies on this site. . Stockhouse. This news release constitutes a. When this page refreshes you will be logged in with the new address. TH | May 19, 2023. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. Losses were -47. . We also use them to share usage. Theratechnologies . 04) earnings per share (EPS) for the quarter. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Further. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. MONTREAL, Feb. com uses cookies on this site. communications@theratech. Christian Marsolais, Ph. The Canadian company develops peptide sequences to treat endocrine and metabolic conditions such as growth hormone deficiencies. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. B2Gold Declares Fourth Quarter 2023 Dividend. TH | October 13, 2022. com. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. Browse posts by Sector and Subsector. Theratechnologies Stock Price, News and Company Updates. ET. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds.